论文部分内容阅读
目的:研究舒利迭辅助治疗慢性阻塞性肺病(COPD)合并肺大泡的临床效果。方法:将92例COPD患者随机分成观察组及对照组,每组46例,均采取常规对症治疗,观察组加用舒利迭连续吸入治疗6个月。观察两组患者的临床疗效及原有肺大泡进展情况和肺大泡新发例数。结果:观察组总有效率为93.5%,优于对照组73.9%(P<0.05);观察组原有肺大泡者有1例数量增加(8.3%),肺大泡新增病例1例(2.2%),对照组原有肺大泡者加重者8例(66.7%),肺大泡新增病例6例(13.0%),观察组显著优于对照组(P<0.01)。结论:舒利迭辅助治疗慢性阻塞性肺病合并肺大泡的疗效肯定,可有效控制肺大泡的进展,降低肺大泡的发生率,适合临床推广应用。
Objective: To study the clinical efficacy of seretide adjuvant in the treatment of chronic obstructive pulmonary disease (COPD) complicated with bullae. Methods: Ninety-two patients with COPD were randomly divided into observation group and control group, with 46 patients in each group. All patients were treated with conventional symptomatic treatment. Patients in observation group were treated with continuous treatment with seretide for 6 months. To observe the clinical efficacy of two groups of patients and the original progress of pulmonary bullae and pulmonary bullae new cases. Results: The total effective rate in the observation group was 93.5%, which was significantly better than that in the control group (73.9%, P <0.05). In the observation group, the number of primary pulmonary bullae was increased in 1 case (8.3%), 2.2%). In the control group, 8 cases (66.7%) had exacerbation of original bullae and 6 cases (13.0%) newly cases of bullae. The observation group was significantly better than the control group (P <0.01). Conclusion: The effect of seretide adjuvant treatment of chronic obstructive pulmonary disease with bullae is sure, which can effectively control the progress of bullae and reduce the incidence of bullae, which is suitable for clinical application.